We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Chemical Analysis of Blood Samples Diagnoses Brain Tumors

By LabMedica International staff writers
Posted on 21 Nov 2019
Brain tumors tend to have ambiguous symptoms, such as headache or memory problems, and a brain scan is currently the only reliable way of diagnosing them. More...
In recent years, the use of infrared (IR) spectroscopy to analyze disease state in biofluids has been largely employed with promising results.

Diagnosis of brain tumors has been previously investigated with attenuated total reflectance Fourier transform infrared (ATR-FTIR) spectroscopy on dried human serum samples to eliminate spectral interferences of the water component. Rapid analysis of liquid samples would represent a promising approach for clinical translation.

A team of scientists at the University of Strathclyde (Glasgow, UK) and their colleagues evaluated ATR-FTIR on both liquid and dried samples to investigate “digital drying” as a novel approach for the analysis of spectra obtained from liquid samples. Quantum cascade laser infrared (QCL-IR) based spectroscopic imaging was also utilized on liquid samples to assess the implications of this novel light source on disease classification. The team tried out the new test on blood samples taken from 400 patients with possible signs of brain tumor who had been referred for a brain scan at the Western General Hospital (Edinburgh, UK).

The team reported that of the 400 patients, 40 were subsequently found to have a brain tumour. Using the test, the scientists were able to correctly identify 82% of brain tumors. The test was also able to correctly identify 84% of people who did not have brain tumors, meaning it had a low rate of 'false’ positives. In the case of the most common form of brain tumor, called glioma, the test was 92% accurate at picking up which people had tumors.

Matthew Baker, PhD, Reader in Chemistry, and chief scientific officer at ClinSpec Diagnostics Ltd (Glasgow, Scotland), where the test was developed, and a senior author of the study, said, “These results are extremely promising because they suggest that our technique can accurately spot who is most likely to have a brain tumour and who probably does not. Because the technique requires just a small blood sample, if offers the potential to test a large number of people with suspicious symptoms and give the best indication of who needs an urgent brain scan. This could ultimately speed up diagnosis, reduce the anxiety of waiting for tests and get patients treated as quickly as possible.” The study was presented at the 2019 NCRI Cancer Conference held November 4- 6, 2019, in Glasgow, UK.

Related Links:
University of Strathclyde
Western General Hospital
ClinSpec Diagnostics Ltd



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Fully Automated Urinalysis System
DxU 1800 Fully Automated Urinalysis System
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image Credit: Shutterstock

Lung Cancer Atlas Reveals Cellular Patterns Associated With Patient Prognosis

Lung cancer is a leading cause of cancer-related death worldwide and is characterized by substantial cellular heterogeneity. Even within a single tumor, cancer cells can vary in aggressiveness, while immune,... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Malaria is caused by Plasmodium parasites, primarily transmitted through the bites of infected female Anopheles mosquitoes (Image Credit: Adobe Stock)

Complete Malaria Genomes Could Improve Species Identification and Surveillance

Malaria remains a major global health challenge, with an estimated 282 million cases and 610,000 deaths worldwide in 2024. Although most research has focused on Plasmodium falciparum, Plasmodium ovale... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.